Geode Capital Management
ADPT icon

Geode Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Geode Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.1M Buy
3,641,837
+5,783
+0.2% +$88.6K ﹤0.01% 1368
2026
Q1 		$50.5M Buy
3,636,054
+124,199
+4% +$1.98M ﹤0.01% 1486
2025
Q4 		$57M Buy
3,511,855
+110,825
+3% +$1.81M ﹤0.01% 1399
2025
Q3 		$50.9M Buy
3,401,030
+185,859
+6% +$2.26M ﹤0.01% 1454
2025
Q2 		$37.5M Buy
3,215,171
+434,347
+16% +$3.95M ﹤0.01% 1582
2025
Q1 		$20.7M Buy
2,780,824
+96,318
+4% +$740K ﹤0.01% 1881
2024
Q4 		$16.1M Buy
2,684,506
+22,628
+0.9% +$125K ﹤0.01% 2076
2024
Q3 		$13.6M Sell
2,661,878
-20,450
-0.8% -$89.1K ﹤0.01% 2189
2024
Q2 		$9.71M Buy
2,682,328
+103,202
+4% +$328K ﹤0.01% 2340
2024
Q1 		$8.28M Buy
2,579,126
+55,484
+2% +$215K ﹤0.01% 2437
2023
Q4 		$12.4M Buy
2,523,642
+107,763
+4% +$492K ﹤0.01% 2215
2023
Q3 		$13.2M Buy
2,415,879
+129,253
+6% +$855K ﹤0.01% 2088
2023
Q2 		$15.3M Buy
2,286,626
+70,646
+3% +$525K ﹤0.01% 2036
2023
Q1 		$19.6M Buy
2,215,980
+70,337
+3% +$620K ﹤0.01% 1817
2022
Q4 		$16.4M Buy
2,145,643
+95,465
+5% +$743K ﹤0.01% 1909
2022
Q3 		$14.6M Buy
2,050,178
+19,793
+1% +$186K ﹤0.01% 1972
2022
Q2 		$16.4M Buy
2,030,385
+615,970
+44% +$5.42M ﹤0.01% 1895
2022
Q1 		$19.6M Sell
1,414,415
-23,947
-2% -$377K ﹤0.01% 1918
2021
Q4 		$40.4M Buy
1,438,362
+46,431
+3% +$1.42M ﹤0.01% 1468
2021
Q3 		$47.3M Buy
1,391,931
+222,728
+19% +$8.06M 0.01% 1328
2021
Q2 		$47.8M Buy
1,169,203
+86,484
+8% +$3.36M 0.01% 1345
2021
Q1 		$43.6M Buy
1,082,719
+46,785
+5% +$2.53M 0.01% 1341
2020
Q4 		$61.3M Buy
1,035,934
+55,124
+6% +$2.84M 0.01% 968
2020
Q3 		$47.7M Buy
980,810
+444,678
+83% +$18.7M 0.01% 942
2020
Q2 		$25.9M Buy
536,132
+68,896
+15% +$2.51M 0.01% 1307
2020
Q1 		$13M Buy
467,236
+240,540
+106% +$6.71M ﹤0.01% 1576
2019
Q4 		$6.78M Sell
226,696
-1,642
-0.7% -$47.2K ﹤0.01% 2269
2019
Q3 		$7.05M Buy
+228,338
New +$9.32M ﹤0.01% 2163

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management's ADPT Position: Q2 2026 in Review

Geode Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 0.16% in Q2 2026, buying an estimated $88.6K and bringing the position to 3,641,837 shares worth $78.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Geode Capital Management first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Geode Capital Management held 3,641,837 shares of Adaptive Biotechnologies worth $78.1M as of Q2 2026.
  • Geode Capital Management bought 5,783 Adaptive Biotechnologies shares in Q2 2026, an estimated $88.6K.
  • Adaptive Biotechnologies made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1368 holding.
  • Geode Capital Management first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.